ACM Biolabs at BioEquity Europe, Milano, May 16 -18, 2022

ACM Biolabs at  BioEquity Europe, Milano, May 16 -18, 2022

We are excited to inform you that Alexander Breidenbach, Chief Development Officer/Chief Business Officer ACM Biosciences, will take the opportunity to represent ACM Biolabs at BioEquity Europe, Europe’s premier international showcase for raising biotechs, taking place in Milan, Italy, May 16-18th. Dr Breidenbach will provide an overview of the company and present ACM’s versatile platform to deliver disease prevention and therapeutics and will be available to for in-person meetings with investors who are registered to attend the conference. 

#acmbiosciences #acmbiolabs #polymersomes #vaccine

Posted: February 14, 2022
doi: https://doi.org/10.1101/2021.01.24.427729

Authors: Jian Hang Lam, Devendra Shivhare, Teck Wan Chia, Suet Li Chew, Gaurav Sinsinbar, Ting Yan Aw, Siamy Wong, Shrinivas Venkatraman, Francesca Wei Inng Lim, Pierre Vandepapeliere, Madhavan Nallani

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of coronavirus disease 2019 (Covid-19), an ongoing global public health emergency. Despite the availability of safe and efficacious vaccines, achieving herd immunity remains a challenge due in part to rapid viral evolution. Multiple variants of concern (VOCs) have emerged, the latest being the heavily mutated Omicron, which exhibits the highest resistance to neutralizing antibodies from past vaccination or infection. Currently approved vaccines generate robust systemic immunity, yet poor immunity at the respiratory tract. We have demonstrated that a polymersome-based protein subunit vaccine with wild type (WT) spike protein and CpG adjuvant induces robust systemic immunity (humoral and T cell responses) in mice. Both antigen and adjuvant are encapsulated in artificial cell membrane (ACM) polymersomes – synthetic, nanoscale vesicles that substantially enhance the immune response through efficient delivery to dendritic cells. In the present study, we have formulated a vaccine candidate with the spike protein from Beta variant and assessed its immunogenicity in golden Syrian hamsters. Two doses of ACM-Beta spike vaccine administered via intramuscular (IM) injection evoke modest serum neutralizing titers that are equally efficacious towards WT and Beta viruses. In contrast, the ACM-WT spike vaccine induces a predominantly WT-specific serum neutralizing response with pronounced reduction in potency towards the Beta variant. Remarkably, immunogenicity of the ACM-Beta spike vaccine is greatly enhanced through intranasal (IN) administration. Following IN challenge with the Beta variant, IM-immunized hamsters are fully protected from disease but not infection, displaying similar peak viral RNA loads in oral swabs as non-vaccinated controls. In contrast, hamsters IN vaccinated with ACM-Beta spike vaccine are protected from disease and infection, exhibiting a ∼100-fold drop in total and subgenomic RNA load as early as day 2 post challenge. We further demonstrate that nasal washes from IN-but not IM-immunized animals possess virus neutralizing activity that is broadly efficacious towards Delta and Omicron variants. Altogether, our results show IN administration of ACM-Beta spike vaccine to evoke systemic and mucosal antibodies that cross-neutralize multiple SARS-CoV-2 VOCs. Our work supports IN administration of ACM-Beta spike vaccine for a next-generation vaccination strategy that not only protects against disease but also an infection of the respiratory tract, thus potentially preventing asymptomatic transmission.

Competing Interest Statement

J.H.L., D.S., T.W.C., S.L.C., S.V., G.S., T.Y.A., S.W. and M.N. are employees of ACM Biolabs Pte Ltd, Singapore. P.V is acting Chief Medical Officer of ACM Biosciences AG, Basel, Singapore.

View this Press Release in German

 Singapore and Basel, Switzerland, March 4, 2022 

 ACM Biolabs, a Singaporean-Swiss biotechnology company focusing on the development of prophylactic and therapeutic vaccines for infectious diseases and therapeutic vaccines for personalized cancer treatment, today announced that its first clinical candidate vaccine, ACM-001, a 2nd generation COVID vaccine, demonstrated broad protection against variants of concerns, including delta and omicron in a variety of preclinical studies. ACM-001 can be given intramuscularly as well as intranasally. 

ACM 001 vaccine is developed based on the company’s proprietary ACM (artificial cell membrane) polymer-based technology. This next generation delivery platform offers flexibility with multiple payloads (proteins to RNA) without requiring ultra-low temperatures for mRNA compared to the current lipids-based platforms. ACM is working on a wide range of products that includes vaccine for immunological therapy for cancer. 

After completion of the preclinical safety testing, the lead program, ACM-001, an adjuvanted SARS-CoV-2 spike protein (beta variant) vaccine, is ready to be tested in humans. The plug-and-play platform allows for quick adaption of the COVID vaccine for future variants as well as combinations as multi-valent vaccines. In addition to being needle and pain-free, an intranasal vaccine is expected to achieve maximum protection already in the upper airways where respiratory viruses first enter the body. 

While the currently approved vaccines resulted in attenuation or prevention of disease, they do not provide mucosal immunity and therefore do not prevent replication of virus in the nasal cavity and hence do not stop transmission of SARS-CoV-2. ACM Biolabs has now published its comprehensive investigation of the significant benefits of intranasal ACM-001 (https://acmbiolabs.com/?p=634). While cross-neutralization against variants of concern, including delta and omicron was seen after intramuscular and intranasal delivery, the virus load in the nasal cavity was 100-fold lower already at day 2 when compared with intramuscular administration suggesting a slowing down in virus spread. The reported preclinical studies have provided critical proof of concept and enabled the design of the Phase 1 clinical trial. Following the regulatory approval, which is expected in the next few weeks, healthy adults who had already received two doses of a COVID vaccine will be included in the study. 

“Currently, most of COVID-19 vaccines in use or development are administered via an intramuscular injection, which produces a rather poor mucosal immune response,” said Professor Onur Boyman, Director of the Clinic for Immunology at the University of Zurich. “Intranasal vaccination is thus an ideal approach to fight respiratory viruses. ACM-001 has now produced very promising preclinical data showing that intranasal vaccination greatly improves mucosal immune responses, which inhibit infection at the site of virus entry.” 

“We are very pleased about the intriguing properties of our ACM platform which hold great potential for the development of urgently needed next-generation Covid-19 vaccines,” said Dr. Madhavan Nallani, Chief Executive Officer of ACM Biolabs. “Now that we successfully completed all regulatory requirements including a comprehensive safety evaluation of our ACM platform and that the clinical trial material for ACM-001 is available we are excited to start the Phase 1 study of ACM-001 within the next weeks.” 

For further information please contact: 

For Investors:

Dr. Alexander Breidenbach
Chief Development Officer
ACM Biosciences
+41 61 975 85 88
office@acmbiosciences.com

For Media:

Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch

About ACM Biolabs 

ACM Biolabs is developing prophylactic and therapeutic vaccines for infectious diseases and therapeutic vaccines for personalized cancer treatment based on its proprietary ACM (Artificial Cell Membranes) polymer-based delivery platform technology. The companies lead program, ACM-001, is an adjuvanted SARS-CoV-2 spike protein (beta variant) vaccine ready to move into Phase 1. 

Founded in Singapore in 2013, ACM Biolabs has established laboratories for research and early manufacturing activities. In 2020 ACM Biosciences, a subsidiary of ACM Biolabs, was established in Basel, Switzerland, to internationalize its development activities. ACM Biosciences leads all clinical and regulatory activities of its pipeline programs. It also coordinates business development discussions with potential partners. 

For further information, please visit: www.acmbiolabs.com. 

Disclaimer 

This press release contains forward-looking statements which are based on current assumptions and forecasts of the ACM Biolabs and ACM Biosciences management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. ACM Biolabs and ACM Biosciences disclaim any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

 Singapur und Basel, Schweiz, 4. März, 2022 

 ACM Biolabs, ein schweizerisch-singapurisches Biotechnologieunternehmen, das sich auf die Entwicklung von prophylaktischen und therapeutischen Impfstoffen gegen Infektionskrankheiten und von therapeutischen Impfstoffen für die personalisierte Krebsbehandlung spezialisiert hat, gab heute bekannt, dass sein klinischer Impfstoffkandidat, ACM-001, ein COVID-Impfstoff der zweiten Generation, in einer Reihe von präklinischen Studien einen breiten Schutz gegen verschiedene SARS-CoV-2 Virusvarianten, einschliesslich Delta und Omicron, gezeigt hat. Im Gegensatz zu den gegenwärtig zugelassenen Impfstoffen gegen SARS-CoV-2 kann ACM-001 sowohl intramuskulär als auch intranasal verabreicht werden. 

ACM-001 basiert auf der patentgeschützten ACM-Technologie (ACM steht für «Artificial Cell Membrane»). Diese revolutionäre Plattform ermöglicht das Verpacken und den Transport von komplexen Molekülen wie beispielsweise Proteine oder mRNA in Zielzellen. Wegen ihrer einzigartigen Flexibilität gehört sie zur nächsten Generation von Enkapsulierungstechnologien. Im Vergleich zu den derzeit verwendeten mRNA Impfstoffen mit Liponanopartikeln (LNP) sind auch keine Gefriertemperaturen für die Lagerung erforderlich. ACM arbeitet an einer breiten Palette von Produkten, darunter auch Impfstoffe für die personalisierte Krebsimmuntherapie. 

Nachdem ACM-001, ein SARS-CoV-2-Spike-Protein-Impfstoff (Beta-Variante) kombiniert mit einem Adjuvans, erfolgreich alle präklinischen Sicherheitstests erfüllt hat, kann diese Vakzine der zweiten Generation in Kürze die klinische Entwicklung starten. Die Plug-and-Play-Plattform ermöglicht eine schnelle Anpassung dieses COVID-Impfstoffs an künftige Varianten. 

Ein intranasaler Impfstoff ist nicht nur nadel- und schmerzfrei, sondern kann bereits dort einen maximalen Schutz bieten, wo Atemwegsviren wie SARS-CoV-2 zuerst in den Körper gelangen. Die derzeit zugelassenen Impfstoffe führen in der Regel zu einer Abschwächung oder Verhinderung der Erkrankung, bieten jedoch keine Schleimhautimmunität und verhindern daher nicht die Replikation des Virus in der Nasenhöhle und somit auch nicht die Übertragung von SARS-CoV-2. ACM Biolabs hat nun eine umfassende Untersuchung der signifikanten Vorteile seines auch intranasal zu verabreichenden Impfstoffkandidaten ACM-001 veröffentlicht (https://acmbiolabs.com/?p=634). 

Während sowohl nach intramuskulärer als auch nach intranasaler Verabreichung eine Kreuzneutralisierung gegen die verschiedenen Virusvarianten, einschliesslich Delta und Omicron, festgestellt wurde, konnte die Viruslast in der Nasenhöhle durch die intranasale Verabreichung bereits am zweiten Tag um das Hundertfache verringert werden, was auf eine Verlangsamung der Virusvermehrung durch die Immunantwort schliessen lässt. Diese präklinischen Studien haben entscheidend dazu beigetragen, die klinische Phase-1-Studie zu planen. Nach behördlicher Genehmigung der Studie, die bereits in den nächsten Wochen erwartet wird, werden gesunde Erwachsene, die eine COVID-Grundimmunisierung erhalten haben, mit ACM-001 immunisiert. 

“Derzeit werden die meisten der verwendeten oder in Entwicklung befindlichen COVID-19-Impfstoffe durch eine intramuskuläre Injektion verabreicht, die eine eher schwache Immunantwort auf den Schleimhäuten hervorruft”, sagte Professor Onur Boyman, Direktor der Klinik für Immunologie der Universität Zürich. “Die intranasale Impfung ist daher ein idealer Ansatz zur Bekämpfung von Atemwegsviren. ACM-001 hat nun sehr vielversprechende präklinische Daten geliefert, die zeigen, dass die intranasale Impfung die Immunreaktion der Schleimhäute stark verbessert, was die Infektion an der Eintrittsstelle des Virus hemmt.” 

“Wir freuen uns sehr über die erneute Bestätigung der vielfältigen Eigenschaften unserer ACM-Plattform, die grosses Potenzial für die Entwicklung der dringend benötigten COVID-19-Impfstoffe der nächsten Generation haben”, sagte Dr. Madhavan Nallani, Chief Executive Officer von ACM Biolabs. “Da wir jetzt alle behördlichen Anforderungen, einschließlich einer umfassenden Sicherheitsbewertung unseres Impfstoffes, erfolgreich abgeschlossen haben und das klinische Testmaterial für ACM-001 zur Verfügung steht, können wir schon in den nächsten Wochen mit der

Für weitere Informationen wenden Sie sich bitte an: Phase-1-Studie beginnen.” 

Für Investoren:

Dr. Alexander Breidenbach
Chief Development Officer
ACM Biosciences
+41 61 975 85 88
office@acmbiosciences.com

Für Medien:

Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch

Über ACM Biolabs 

ACM Biolabs entwickelt prophylaktische und therapeutische Impfstoffe gegen Infektionskrankheiten sowie therapeutische Impfstoffe für die personalisierte Krebsbehandlung auf der Grundlage der firmeneigenen polymerbasierten ACM-Plattformtechnologie (ACM – Artificial Cell Membranes). Das führende Programm des Unternehmens, ACM-001, ist ein adjuvantierter SARS-CoV-2-Spike-Protein-Impfstoff (Beta-Variante). Eine erste Phase 1 Studie steht kurz vor dem Start. 

ACM Biolabs wurde 2013 in Singapur gegründet und unterhält dort Labore für Forschung und frühe Produktionsaktivitäten. Im Jahr 2020 wurde ACM Biosciences als Tochtergesellschaft von ACM Biolabs in Basel, Schweiz, gegründet, um vor allem die Entwicklungsaktivitäten zu internationalisieren. ACM Biosciences leitet alle klinischen und regulatorischen Aktivitäten der ACM-Programme und koordiniert auch die Geschäftsentwicklungsgespräche mit potenziellen Partnern. 

Für weitere Informationen: www.acmbiolabs.com. 

Disclaimer 

Diese Pressemitteilung enthält in die Zukunft gerichtete Aussagen, die auf derzeitigen Annahmen und Prognosen der Unternehmensleitung von ACM Biolabs und ACM Biosciences beruhen. Bekannte und unbekannte Risiken, Ungewissheiten und andere Faktoren können dazu führen, dass die tatsächliche Entwicklung wesentlich von den hier gemachten zukunftsgerichteten Aussagen abweicht. Die Leserinnen und Leser werden davor gewarnt, sich in unangemessener Weise auf zukunftsgerichtete Aussagen zu verlassen, da diese nur das Datum dieser Mitteilung widerspiegeln. ACM Biolabs und ACM Biosciences lehnen jede Verpflichtung ab, zukunftsgerichtete Aussagen zu aktualisieren und zu überarbeiten, sei es aufgrund neuer Informationen, zukünftiger Ereignisse oder aus anderen Gründen. 

Posted: January 25, 2021
doi: https://doi.org/10.1101/2021.01.24.427729

Authors: Jian Hang Lam, Amit Kumar Khan, Thomas Andrew Cornell, Regine Josefine Dress, Teck Wan Chia, Wen Wang William Yeow, Nur Khairiah Mohd-Ismail, Shrinivas Venkatraman, Kim Tien Ng, Yee-Joo Tan, Danielle E. Anderson, Florent Ginhoux, Madhavan Nallani

Abstract

Multiple successful vaccines against SARS-CoV-2 are urgently needed to address the ongoing Covid-19 pandemic. In the present work, we describe a subunit vaccine based on the SARS-CoV-2 spike protein co-administered with CpG adjuvant. To enhance the immunogenicity of our formulation, both antigen and adjuvant were encapsulated with our proprietary artificial cell membrane (ACM) polymersome technology. Structurally, ACM polymersomes are self-assembling nanoscale vesicles made up of an amphiphilic block copolymer comprising of polybutadiene-b-polyethylene glycol and a cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane. Functionally, ACM polymersomes serve as delivery vehicles that are efficiently taken up by dendritic cells, which are key initiators of the adaptive immune response. Two doses of our formulation elicit robust neutralizing titers in C57BL/6 mice that persist at least 40 days. Furthermore, we confirm the presence of memory CD4+ and CD8+ T cells that produce Th1 cytokines. This study is an important step towards the development of an efficacious vaccine in humans.

Competing Interest Statement

The authors declare the following competing financial interests: D.E.A. and Y.J.T. developed the cPass kit; J.H.L, A.K.K., T.A.C., T.W.C., W.W.W.Y., and M.N. are employees of ACM Biolabs Pte Ltd; F.G. is part of the ACM SAB. The authors declare no non-financial competing interests.

J.P. Morgan 40th Annual Healthcare Conference 2022 DIGITAL

Date: 2022-01-10 start / 2022-01-13 end

Posted: 2021 Oct 26;15(10)
doi: 10.1021/acsnano.1c01243 · PMID: 34618423 · PMCIDPMC8525042

Authors: Jian Hang Lam 1, Amit K Khan 1, Thomas A Cornell 1, Teck Wan Chia 1, Regine J Dress 2, Wen Wang William Yeow 1, Nur Khairiah Mohd-Ismail 3, Shrinivas Venkataraman 1, Kim Tien Ng 3, Yee-Joo Tan 3 4, Danielle E Anderson 5, Florent Ginhoux 2 6, Madhavan Nallani 1

Abstract

Multiple successful vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are urgently needed to address the ongoing coronavirus disease 2019 (Covid-19) pandemic. In the present work, we describe a subunit vaccine based on the SARS-CoV-2 spike protein coadministered with CpG adjuvant. To enhance the immunogenicity of our formulation, both antigen and adjuvant were encapsulated with our proprietary artificial cell membrane (ACM) polymersome technology. Structurally, ACM polymersomes are self-assembling nanoscale vesicles made up of an amphiphilic block copolymer comprising poly(butadiene)-b-poly(ethylene glycol) and a cationic lipid, 1,2-dioleoyl-3-trimethylammonium-propane. Functionally, ACM polymersomes serve as delivery vehicles that are efficiently taken up by dendritic cells (DC1 and DC2), which are key initiators of the adaptive immune response. Two doses of our formulation elicit robust neutralizing antibody titers in C57BL/6 mice that persist at least 40 days. Furthermore, we confirm the presence of functional memory CD4+ and CD8+ T cells that produce T helper type 1 cytokines. This study is an important step toward the development of an efficacious vaccine in humans.

Keywords: ACM; Covid-19; neutralizing antibody; polymersome; spike; vaccine.

Conflict of interest statement

The authors declare the following competing financial interest(s): D.E.A. developed the cPass kit; J.H.L, A.K.K., T.A.C., T.W.C., W.W.W.Y., S.V., and M.N. are employees of ACM Biolabs Pte Ltd; F.G. is part of the ACM SAB.

ACM Biosciences and Dr. Steve Pascolo, University Hospital Zurich awarded a prestigious Innosuisse grant to partner and develop stable mRNA COVID-19 vaccines

Basel, 27 May 2021 – ACM Biosciences AG, a Swiss biotechnology company focusing on the development of their proprietary polymersome-based vaccines, today announced that Innosuisse, the Swiss Innovation Agency, has awarded a grant for the development of a novel delivery system for mRNA COVD-19 vaccines. Dr. Steve Pascolo, global expert in mRNA vaccines and group leader at the University Hospital Zurich, and ACM Biosciences will join forces to develop a stable and novel carrier for mRNA with improved properties regarding storage at refrigerator temperature, logistics, and flexibility.

mRNA-based vaccines are one of the most important scientific breakthroughs arising from the COVID-19 pandemic. However, these vaccines are burdened with drawbacks that limit their widespread use. Specifically, they are unstable, requiring complex cooling solutions for transport and storage, and the manufacturing of the final product is complex and costly. With this project, ACM Biosciences aims to maximize the potential of mRNA vaccines by developing a novel vaccine carrier system to improve their efficacy, stability, and cost effectiveness. The proprietary Artificial Cell Membranes (ACMs) from ACM Biosciences are based on an innovative nanotechnology platform using non-immunogenic polymersomes as its stable carrier. In parallel to this project, the company is developing a sub-unit protein based COVID-19 vaccine candidate in clinical trials and is conducting an mRNA proof of concept stability and immunogenicity study.

Dr. Steve Pascolo, Principal Investigator at the University Hospital Zurich and co-founder of CureVac, a leading mRNA company, commented:

“A polymersome carrier would have a simpler structure than a lipid nanoparticle carrier, which is the current standard for mRNA vaccines. This could yield clear benefits such as higher stability with easier storage and handling, cheaper production and making global supply possible even in areas with poor infrastructure.”

“We are delighted to collaborate with Dr. Steve Pascolo with the support from Innosuisse to validate the polymersomes for mRNA delivery,” added Dr. Peter Moran, CEO of ACM Biosciences. “Through this public-private partnership, ACM Biosciences will push this platform as a stable mRNA vaccine closer to clinics. We are excited with this opportunity to strengthen our pipeline of polymersome-based vaccines as a highly effective and stable carrier.

About ACM
Biosciences ACM Biosciences was incorporated in Basel, Switzerland, in 2020 as the human infectious disease vaccine company of ACM Biolabs, which is based in Singapore, a leader in protein vaccines and novel nanoparticle delivery techniques in the oncology and veterinary fields. ACM Biosciences is dedicated to the development of infectious disease vaccines using the proprietary ACM polymersome platform technology. These artificial cell membranes (ACM) are nanoscale vesicles that are conceptually very similar to liposomes and have shown to have numerous advantages for both veterinary and human vaccines, including viral, bacterial, and oncological diseases. ACM Biosciences is now accelerating a COVID-19 vaccine into clinical trials. For further information, please visit: www.acmbiosciences.com

  • ACM Biosciences vaccines have been successfully developed against coronavirus in animal health
  • ACM Biosciences provides a flexible, scalable, easy to manufacture and highly efficacious vaccine platform

Basel, 7 April 2021 – ACM Biosciences AG, a Swiss biotechnology company focusing on the development of polymersome-based vaccines, today announced the closing of a first financing round to advance its human vaccines platform and a second-generation Covid-19 vaccine. ACM Biosciences secured the exclusive worldwide license to the proprietary polymersome platform for the development of human infectious disease vaccines from ACM Biolabs Pte Ltd in Singapore, which is a leader in protein vaccines and novel nanoparticle delivery techniques in the oncology and veterinary fields.

Dr Peter Moran, CEO of ACM Biosciences, commented:

“With the great results we have seen so far from our technology in animal health, this financing is a key step in our strategy and will provide the necessary financial resources to progress both the COVID-19 vaccine candidate into clinical trials and the mRNA proof of concept stability and immunogenicity study.”

Focus on fast, efficient development of clinical vaccine candidates

The proprietary Artificial Cell Membranes (ACMs) are based on an innovative nanotechnology platform using non-immunogenic polymersomes as its carrier. Through past developments by ACM Biolabs in Singapore, the ACM polymersome platform has been shown to produce a safe and efficacious veterinary vaccine against porcine epidemic diarrhea, a highly contagious and deadly coronavirus in pigs, for which there is no effective commercial vaccine. By working closely together, the Singapore and Swiss entities have developed a protein-based COVID-19 vaccine which shows an excellent immune response in preclinical trials. With the necessary financial resources secured, ACM Biosciences will now accelerate its development of the COVID-19 vaccine candidate and proceed with the running mRNA vaccine proof of concept stability and immunogenicity studies.

Prof Dr Daniel Paris, Medical Director and Head of the Department of Medicine at Swiss Tropical and Public Health Institute commented:

“ACM Biosciences’ technology has the potential to bring a step-change in manufacturability, and durability of vaccines, something Press Release ACM Biosciences AG, Steinenberg 1, 4051 Basel; www.acmbiosciences.com Page 2 of 2 which is urgently needed for a long-term solution to COVID-19, but also for other vaccine preventable diseases. Their preclinical efficacy data are really exciting, and their vaccine candidate should be taken into clinical trials as quickly as possible.”

Polymersome platform offers advantages in manufacturability and increases durability of vaccines

ACM Biosciences technology allows great variability because its polymersome platform is highly customizable and can be made compatible with different vaccine formats, including mRNA and protein antigens. A formulation with polymersomes also enables a vaccine to be delivered intranasally, which is not only a convenient route of administration but can reduce transmissibility by activating mucosal immunity. Furthermore, polymersomes do not suffer from vector neutralizing antibodies, are very stable for easy storage and shipping and do not need a complex cold chain. And they can be manufactured cost-effective and with scale. As such, the platform allows quick adjustability to new strains and is well suited for repetitive use and applications.

Prof Dr Onur Boyman, Professor and Chair of the Department of Immunology at the University of Zurich added:

“ACM Biosciences’ next-generation vaccines can readily be adapted to emerging mutant viruses, which is crucial to control infection with SARS-CoV-2 and with other viral diseases.”

About ACM Biosciences
ACM Biosciences was incorporated in Basel, Switzerland, in 2020 as the human infectious disease vaccine company of ACM Biolabs, which is based in Singapore, a leader in protein vaccines and novel nanoparticle delivery techniques in the oncology and veterinary fields. ACM Biosciences is dedicated to the development of infectious disease vaccines using the proprietary ACM polymersome platform technology. These artificial cell membranes (ACM) are nanoscale vesicles that are conceptually very similar to liposomes and have shown to have numerous advantages for both veterinary and human vaccines, including viral, bacterial, and oncological diseases. ACM Biosciences is now accelerating a COVID-19 vaccine into clinical trials. For further information, please visit: www.acmbiosciences.com

Posted: 20 jan. 2011
Citation: Chem. Commun., 2011,47, 2862-2864

Authors: Zhikang Fu,a   Mirjam Andreasson Ochsner,a   Hans-Peter M. de Hoog,b   Nikodem Tomczak*a  and  Madhavan Nallani*ab  

Abstract

Multicompartmentalized polymersomes are formed using block co-polymers PMOXA–PDMS–PMOXA and PS-PIAT, and are subsequently proven to be capable of selective encapsulation of biomacromolecules. This architecture mimics the compartmentalization found in cells and may serve as a simple, albeit robust, model system.